As we have reached the end of February, we review moves from smid-cap biopharma companies during this past week as well as for the month of February See Table 1 for weekly moves and moves YTD for companies and categories on BPIQ.com compared to XBI.
Table 1. BPIQ company weekly moves and YTD moves
Highlights for the week of 2/28 - 3/4
Biggest positive move
$ATXI +236%
Biggest negative move
$NCNA -65.6% Phase 3 Biliary Tract Cancer Study recommended to be discontinued
Additional big moves
$BCEL +195.5% Atreca Reports Fourth Quarter and Full-Year 2021 Financial Results and ATRC-101 Data Update
$CTIC +66.2% CTI BioPharma Announces FDA Accelerated Approval of VONJO™ (pacritinib) for the Treatment of Adult Patients with Myelofibrosis and Thrombocytopenia.
$TNXP +33.1% Tonix Pharmaceuticals Announces FDA Orphan-Drug Designation for TNX-2900 for the Treatment of Prader-Willi Syndrome
$IFRX -11.6% InflaRx Provides Update on Development Plans for Vilobelimab in Hidradenitis Suppurativa.
$AMYT -14.2% Amryt Receives Complete Response Letter from the FDA for Oleogel-S10 NDA.
$CYAD -17.1% Celyad Oncology Announces Voluntary Pause of CYAD-101-002 Phase 1b Trial.
$MDWD -21.8% MediWound Ltd. Announces Proposed Public Offering of Ordinary Shares
$OCGN -23.1% Ocugen Provides an Update on its COVAXIN™ Pediatric (2-18) Emergency Use Authorization (EUA) Request.
Highlights for February 2022
Biggest positive move
$LNTH +88.2% Lantheus Receives U.S. FDA Approval of New Manufacturing Facility
Biggest negative move
$SYGGF -85.6% Topline results from Phase 3 SPRINTER trial (Did not meet endpoints)
Highlights for next week
Companies with commercial assets reporting Q4 '21 results next week:
$EGRX
$AQST
$OPTN
$ACRX
4ZEAL
$URGN
$XERS
$PLXP
Watch over the next few weeks for quarterly company reports including commercial sales
See our Big Movers post to learn about the upcoming March Big Movers/Movers to Watch
Comentários